Chemotherapy strategies in ENT. Ms ent university exam pattern for 20 marks.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the content I need for a comprehensive 20-mark university exam answer. Let me compile the complete answer.

Chemotherapy Strategies in ENT (Head and Neck Oncology)

20-Mark University Exam Answer

Introduction

Chemotherapy in ENT refers to the use of anticancer drugs in the management of head and neck squamous cell carcinomas (HNSCC) and other malignancies of the ENT region. Since the 1940s, significant advances have been made from nitrogen mustard-based agents to modern targeted therapies and immunotherapy. The goal is to exploit the differences in proliferative characteristics between normal and malignant cells.

(Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol 1, Ch. 4)

Principles of Chemotherapy

Chemotherapy aims to exploit the resulting differences in biological and proliferative characteristics between normal and cancer cells, where most cytotoxic drugs preferentially affect dividing cells in tumours. The cell cycle consists of:

G0 - resting phase
G1 - growth phase (cell increases in size, prepares to copy DNA)
S (Synthesis) - doubling of chromosomal material
G2 - further growth phase before division
M (Mitosis) - chromosomes separate, cell divides

Fractional Cell Kill Hypothesis: Each dose of chemotherapy kills a fixed fraction of cancer cells. A gap between cycles allows normal tissue to recover.

Classification of Chemotherapeutic Agents

1. Alkylating Agents

Act by covalently binding to and cross-linking DNA strands. Examples:

Cyclophosphamide - prodrug activated in the liver
Cisplatin and carboplatin (platinum compounds) - bind to DNA causing cross-links; most important agents in head and neck cancer
Ifosfamide, chlorambucil

2. Antimetabolites

Interfere with DNA synthesis by mimicking or inhibiting normal metabolites. Phase-specific (S-phase):

Methotrexate - inhibits dihydrofolate reductase, blocking purine/thymidylate synthesis; used in head and neck cancer
5-Fluorouracil (5-FU) - inhibits thymidylate synthetase; widely used with cisplatin (PF regimen)
Gemcitabine - gaining favour in head and neck cancer trials
Capecitabine - oral prodrug of 5-FU

3. Cytotoxic Antibiotics

Derived from bacterial/fungal cultures (often Streptomyces species):

Anthracyclines (doxorubicin, daunorubicin, epirubicin) - intercalate DNA, inhibit topoisomerase II
Bleomycin - glycopeptide mixture causing DNA fragmentation; used in lymphoma (ABVD), also historically used in head and neck
Mitomycin C - alkylating agent, cross-links DNA
Actinomycin D - intercalates between guanine-cytosine pairs, blocks RNA synthesis

4. Spindle Poisons (M-phase specific)

Vinca alkaloids (vincristine, vinblastine) - bind tubulin, inhibit microtubule assembly during metaphase
Other examples: vindesine, vinorelbine

5. Taxoids (M-phase specific)

Paclitaxel (Taxol) and docetaxel (Taxotere) - promote assembly of microtubules and inhibit their disassembly; activate apoptotic pathways

6. Topoisomerase Inhibitors

Topoisomerase I inhibitors: irinotecan, topotecan (camptothecins)
Topoisomerase II inhibitors: etoposide, teniposide (epipodophyllotoxins)

Chemotherapy Strategies in Head and Neck Cancer

1. Combination Chemotherapy

Combinations of cytotoxic agents are more effective than single agents because they:

Expose tumour to agents with different mechanisms of action
Have non-overlapping toxicities
Reduce drug resistance
Exploit synergistic interactions

Cisplatin is the backbone of combination chemotherapy in head and neck cancers. The standard regimen is cisplatin + 5-FU (PF regimen). The TPF regimen (docetaxel + cisplatin + 5-FU) has shown superior outcomes in recent trials.

2. Adjuvant Chemotherapy

Given after curative surgery or radiotherapy in patients at high risk of relapse
Intention: eradicate micrometastatic disease
Randomized trials do not suggest a significant survival benefit for adjuvant chemotherapy alone in HNSCC [Level 1 evidence]

3. Neoadjuvant (Induction) Chemotherapy

Chemotherapy given before definitive surgery or radiotherapy in locally advanced disease
Rationale: reduce tumour bulk, improve local/distant control, achieve organ preservation

Key Trials:

VA Laryngeal Cancer Study Group: Induction cisplatin/5-FU followed by radiotherapy vs. surgery + radiotherapy in Stage III/IV disease. Result: 85% chemotherapy response rate; no survival difference, but laryngeal preservation achieved in responders.
RTOG 91-11 Trial: Randomized 547 patients (Stage III/IV) to:
1. Induction cisplatin/5-FU → radiotherapy
2. Concurrent cisplatin-based chemoradiotherapy (CRT)
3. Radiotherapy alone
Result: Concurrent CRT was superior to induction chemotherapy or radiotherapy alone for organ preservation and locoregional control; no difference in overall survival.
TPF (Docetaxel-Cisplatin-5-FU) induction combinations appear superior to cisplatin-5-FU in overall survival, progression-free survival, locoregional and distant failure for loco-regionally advanced disease. However, toxicity is high.

Current status: Neoadjuvant chemotherapy remains controversial and is considered on a case-by-case basis [Level 1 evidence].

4. Concurrent Chemoradiation (CRT)

Synchronous use of chemotherapy and radiotherapy (most common strategy)
Often used after definitive surgery or as primary treatment in unresectable disease

Mechanisms of radiosensitization by chemotherapy:

Inhibits tumour repopulation
Preferentially kills hypoxic cells
Inhibits repair of sublethal radiation damage
Sterilizes micrometastatic disease outside radiation fields
Decreases tumour mass → improved blood supply and reoxygenation

Fractionated radiotherapy in turn sensitizes to chemotherapy by inhibiting repair of drug-induced damage and improving blood supply/drug delivery.

Evidence:

Two pivotal Phase III studies - RTOG 9501 and EORTC 22931: Demonstrated improved locoregional control with addition of chemotherapy in high-risk patients
High-risk features warranting adjuvant CRT: positive lymph nodes, positive margins, extracapsular spread (ECS), perineural/vascular invasion
A post-hoc analysis confirmed ECS and positive margins are the most important indications for adjuvant chemoradiation
Patients with these features show an improved 5-year survival by 13% with CRT

5. Palliative Chemotherapy (Recurrent/Metastatic Disease)

Patients with recurrent or metastatic HNSCC have median overall survival under 1 year
Recurrence rate in early-stage HNSCC: ~10-20%; in locally advanced: ~50%
Only a small percentage can be treated with curative intent; the majority receive palliative chemotherapy

EXTREME Trial (First-line palliative):

Cisplatin/carboplatin + 5-FU ± cetuximab
Addition of cetuximab to chemotherapy improved median survival (~10 months with cetuximab vs ~7.4 months without)
Response rates approximately 20%; median survival ~5-6 months with chemotherapy alone

Novel / Targeted Therapies

EGFR-Targeted Therapy

EGFR (Epidermal Growth Factor Receptor) is overexpressed in a large number of HNSCCs
Overexpression associated with increased proliferative capacity, metastatic potential, and independent poor prognosis
EGFR blockade inhibits proliferation and influences angiogenesis, cell motility, and invasion

Cetuximab:

Chimeric IgG monoclonal antibody against EGFR
Binding affinity equal to natural ligand; blocks effect of EGF and TGF-α
Causes internalization of EGFR and targets cytotoxic immune effectors toward EGFR-expressing tumour cells
Addition of cetuximab to radiotherapy improves locoregional control and survival vs. primary radiotherapy alone [Level 1 evidence]
Cetuximab-radiotherapy is an option for patients unable to receive cisplatin-based CRT (not shown to be superior to standard CRT)

Small Molecule Tyrosine Kinase Inhibitors: e.g., gefitinib, erlotinib - target the intracellular domain of EGFR; clinical trials ongoing

Anti-VEGF Therapy

VEGF (Vascular Endothelial Growth Factor) is a multifunctional cytokine released in response to hypoxia; important stimulator of angiogenesis
High VEGF expression in certain HNSCCs is associated with higher tumour proliferation rate and worse survival
Bevacizumab (Avastin) - humanized murine monoclonal antibody targeting VEGF; first anti-angiogenic drug to show survival advantage in cancer therapy; clinical trials exploring combination with EGFR-targeted drugs

Immunotherapy

Immune checkpoint inhibitors represent the newest class of systemic agents:

Function by interrupting immunosuppressive pathways (inhibitory checkpoints) that tumour cells use to evade host immune system

Molecular targets:

CTLA-4 (cytotoxic T-lymphocyte antigen-4) on T cells
PD-1 (programmed cell death protein 1) receptor on T cells
PD-L1 - ligand found on both tumour and immune cells; ligand to PD-1

Pembrolizumab and nivolumab (anti-PD-1 agents) have shown activity in recurrent/metastatic HNSCC.

Clinical evidence:

Objective response rates ~20% in patients who progressed on first-line chemotherapy combinations for recurrent/metastatic HNSCC
PD-L1 expression correlates with better efficacy but is not definitive
Currently indicated for patients with very advanced disease who progress on standard first-line chemotherapy
Ongoing studies in both locally advanced and metastatic settings

Summary Table

Strategy	Timing	Aim	Key Agent(s)	Evidence
Adjuvant chemotherapy	After definitive Rx	Eradicate micrometastases	Cisplatin	No survival benefit (Level 1)
Neoadjuvant/Induction	Before definitive Rx	Organ preservation, ↓ bulk	Cisplatin+5FU, TPF	VA study, RTOG 91-11
Concurrent CRT	With radiotherapy	Radiosensitization, locoregional control	Cisplatin	RTOG 9501, EORTC 22931
Palliative	Recurrent/metastatic	Palliation, ↑ survival	Cisplatin+5FU ± Cetuximab	EXTREME trial
Targeted	Any advanced stage	Specific pathway inhibition	Cetuximab, Bevacizumab	Level 1 (cetuximab)
Immunotherapy	Refractory/advanced	Immune evasion disruption	Pembrolizumab, Nivolumab	~20% ORR in salvage

Conclusion

Chemotherapy in ENT/head and neck oncology is multimodal. Concurrent chemoradiation with cisplatin is the gold standard for locally advanced unresectable disease and adjuvant high-risk settings. Induction chemotherapy with TPF regimens is reserved for select cases. For recurrent/metastatic disease, the EXTREME regimen (platinum + 5-FU + cetuximab) remains the standard first-line option, while immune checkpoint inhibitors (pembrolizumab, nivolumab) represent the most important recent advance for platinum-refractory disease.

Sources:

Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol 1, Chapter 4 (Sarah Payne & David Miles) - Chemotherapy in Head and Neck Cancer
Cummings Otolaryngology Head and Neck Surgery

This is a shared conversation. Sign in to Orris to start your own chat.